Pamiparib (BGB-290) is a potent, brain-penetrant, and selective PARP1/2 inhibitor with strong PARP-trapping activity. It is widely used in preclinical cancer research, demonstrating efficacy in both in vitro assays and in vivo models for solid tumors, including those with central nervous system involvement.